Last updated: February 27, 2026
What is QTERNMET and its formulation profile?
QTERNMET is a fixed-dose combination drug used for type 2 diabetes management. It combines dapagliflozin (SGLT2 inhibitor), saxagliptin (DPP-4 inhibitor), and metformin. The formulation includes active pharmaceutical ingredients (APIs) with specific excipient requirements to optimize stability, bioavailability, and patient tolerability.
What are the key excipient considerations for QTERNMET?
The formulation requires excipients that:
- Ensure solubility and stability of APIs.
- Minimize gastrointestinal irritation from metformin.
- Support controlled release if applicable.
- Comply with regulatory standards for combination tablets.
Typical excipients include diluents, binders, disintegrants, flow agents, and coating agents, with specific choices tailored to the APIs’ physicochemical properties.
Common excipient types and their roles:
| Excipient Type |
Function |
Examples |
| Diluents |
Provide bulk to low-dose APIs |
Microcrystalline cellulose, lactose |
| Binders |
Facilitate granule formation and tablet integrity |
Polyvinylpyrrolidone, hydroxypropyl cellulose |
| Disintegrants |
Promote tablet breakup for rapid dissolution |
Croscarmellose sodium, sodium starch glycolate |
| Lubricants |
Reduce friction during compression |
Magnesium stearate, stearic acid |
| Glidants |
Improve flowability of powders |
Colloidal silicon dioxide |
Excipients are selected to match the drug release profile, minimize adverse effects, and enhance manufacturability.
What are the manufacturing and stability considerations?
QTERNMET’s multi-API formulation demands excipients that:
- Are compatible with all APIs in the formulation.
- Support stability under storage conditions, typically at 25°C/60% RH.
- Prevent degradation, especially of sensitive APIs like saxagliptin.
- Facilitate scale-up and consistent batch production.
Accelerated stability testing informs excipient choice, targeting a shelf life of at least 24 months.
What are the main commercial opportunities for excipients in QTERNMET?
Market size for excipients in diabetes combination drugs
The global excipient market for oral solid dosage forms was valued at approximately $5.2 billion in 2022. The diabetes segment, driven by the increasing prevalence of type 2 diabetes, accounts for a significant share.
Opportunities in excipient development
- Specialized excipients: Polymers that improve controlled release, such as ethylcellulose or methacrylate-based coatings.
- Enhanced bioavailability: Lipid-based excipients (e.g., phospholipids) improving solubility of APIs.
- Patient-centric formulations: Flavoring agents and taste-masking excipients for better adherence.
Strategic considerations for manufacturers
- Differentiation through innovative excipients that extend shelf life or improve bioavailability.
- Formulation of low excipient volume tablets to meet patient preferences.
- Collaboration with excipient suppliers to develop regulatory-compliant, proprietary materials.
How do regulatory standards impact excipient selection?
International regulatory agencies (FDA, EMA) specify excipient safety requirements. The excipient must be Generally Recognized As Safe (GRAS) or have an approved excipient monograph. For combination products like QTERNMET, the excipient must:
- Be compatible with multiple APIs.
- Meet pharmacopoeial standards (USP, EP, JP).
- Pass extractables and leachables testing protocols.
What is the competitive landscape?
Leading excipient suppliers include Evonik, FMC Biopolymer, Merck KGaA (EMD), and Bend Research. These companies have advanced excipient portfolios suited for complex formulations.
| Supplier |
Focus Area |
Key Products |
| Evonik |
Functional excipients for controlled release |
Collidon, Purified cellulose |
| FMC Biopolymer |
Biopolymer-based binders and disintegrants |
Ac-Di-Sol, Fibersol |
| Merck KGaA |
Well-established excipient standards |
Lactose, Microcrystalline cellulose |
Strategies include developing proprietary excipients with improved performance and regulatory advantages.
What are the key challenges and strategies?
- API-excipient compatibility: Conduct thorough compatibility studies.
- Regulatory compliance: Ensure excipient sources meet global standards.
- Manufacturability: Optimize excipient grades to facilitate processing.
- Patent landscape: Secure intellectual property around novel excipient compositions.
Partnerships with excipient manufacturers can streamline development and regulatory approval processes.
Final insights
QTERNMET’s formulation demands careful excipient selection aligning with stability, bioavailability, manufacturability, and regulatory compliance. Innovations in excipient technology can unlock commercial opportunities, particularly in developing controlled-release formulations, taste-masked tablets, and enhanced bioavailability products.
Key Takeaways
- Excipient selection impacts the stability, bioavailability, and tolerability of QTERNMET.
- The global excipient market is growing, driven by the rise in diabetes prevalence and complex formulations.
- Proprietary excipients or innovative coating technologies offer competitive advantages.
- Regulatory compliance, compatibility, and manufacturability influence excipient strategy.
- Collaborations with excipient suppliers can accelerate product development and market entry.
FAQs
1. Which excipients are critical for minimizing gastrointestinal irritation from metformin?
Mucoadhesive polymers and coatings, such as hydroxypropyl methylcellulose, help reduce GI discomfort by controlling drug release.
2. Can targeted excipient modifications improve QTERNMET’s shelf life?
Yes. Stabilizing excipients like antioxidants or moisture scavengers enhance shelf stability.
3. Are there opportunities for incorporating taste-masking excipients?
Yes. Bitter APIs like saxagliptin benefit from flavoring agents or taste-masking polymers to aid patient compliance.
4. How do controlled-release excipients affect QTERNMET’s efficacy?
They can provide sustained API release, reducing dosing frequency and improving adherence.
5. What factors influence excipient choice during scale-up?
Flowability, compression behavior, and batch-to-batch consistency are critical during scale-up, affecting process efficiency and product quality.
Citations:
[1] Sharma, S., et al. (2022). Pharmaceutical excipients in drug delivery. Drug Development and Industrial Pharmacy, 48(2), 232-245.
[2] U.S. Food and Drug Administration. (2021). Guidance for Industry: Nonclinical Considerations for Demonstrating Biosimilarity to a Reference Product.
[3] European Medicines Agency. (2020). Guideline on the quality of oral modified release products.
